The Speers laboratory research includes nomination and validation of expression-based signatures to predict patients that need treatment intensification and signatures to identify patient who will not need further adjuvant therapy for breast cancer. Moreover, our translational work has credentialed a number of novel targets for the treatment of estrogen and progesterone receptor-negative, HER2-negative “triple-negative” breast cancer, a particularly aggressive and difficult to treat form of breast cancer. As PI or co-Investigator on several university-, industry-, private foundation- and NIH-funded grants, we remain active in the radiation and breast cancer research arena by looking for more effective, targeted therapies for women with breast cancer. These targeted therapies include PARP-inhibitors, BET bromodomain inhibitors, and androgen receptor antagonists as agents for radiosensitization. We have also utilized kinome screens to identify novel targets for the treatment of aggressive breast cancers, including triple-negative breast cancer. Finally, we are also interested in the mechanisms of treatment resistance that include modulation of breast tumor initiating cells and understanding novel layers of cancer biology, including the role of long non-coding RNA in triple-negative breast cancer.
Clinical and scientific interests include using genomic and proteomic approaches to identify women who are at high risk for breast cancer recurrence and who may benefit from treatment intensification. Interests also include molecularly based signatures to identifying women who are cured after breast conserving surgery and who may not require adjuvant radiation.
Radiation Therapy for Breast Cancer
Radiation therapy for breast cancer- Interest includes identifying novel molecular targets for chemo‐ and radio-sensitization in women with triple‐negative or basal‐like breast cancer, including those molecules critical for maintaining breast cancer stem cells.
Radiation Therapy for Prostate Cancer
Radiation therapy for prostate cancer- Interest includes the identification of molecular targets relevant for the systemic progression and radiation sensitization of prostate cancer.
TTK inhibition radiosensitizes basal-like breast cancer through impaired homologous recombination. Chandler BC, Moubadder L, Ritter CL, Liu M, Cameron M, Wilder-Romans K, Zhang A, Pesch AM, Michmerhuizen AR, Hirsh N, Androsiglio M, Ward T, Olsen E, Niknafs YS, Merajver S, Thomas DG, Brown PH, Lawrence TS, Nyati S, Pierce LJ, Chinnaiyan A, Speers C. J Clin Invest. 2020 Jan 21. pii: 130435. doi: 10.1172/JCI130435. [Epub ahead of print], PMID: 31961339
RadioGx: A New Preclinical Tool to Model Intrinsic Radiosensitivity. Spratt DE, Speers C. Cancer Res. 2019 Dec 15;79(24):6076-6078. doi: 10.1158/0008-5472.CAN-19-3277. PMID: 31836601
Clinicogenomic Radiotherapy Classifier Predicting the Need for Intensified Locoregional Treatment After Breast-Conserving Surgery for Early-Stage Breast Cancer. Sjöström M, Chang SL, Fishbane N, Davicioni E, Zhao SG, Hartman L, Holmberg E, Feng FY, Speers CW, Pierce LJ, Malmström P, Fernö M, Karlsson P. J Clin Oncol. 2019 Dec 10;37(35):3340-3349. doi: 10.1200/JCO.19.00761. Epub 2019 Oct 16. PMID: 31618132
Comprehensive Transcriptomic Profiling Identifies Breast Cancer Patients Who May Be Spared Adjuvant Systemic Therapy. Sjöström M, Chang SL, Fishbane N, Davicioni E, Hartman L, Holmberg E, Feng FY, Speers CW, Pierce LJ, Malmström P, Fernö M, Karlsson P. Clin Cancer Res. 2020 Jan 1;26(1):171-182. doi: 10.1158/1078-0432.CCR-19-1038. Epub 2019 Sep 26. PMID: 31558478
PARP1 Inhibition Radiosensitizes Models of Inflammatory Breast Cancer to Ionizing Radiation. Michmerhuizen AR, Pesch AM, Moubadder L, Chandler BC, Wilder-Romans K, Cameron M, Olsen E, Thomas DG, Zhang A, Hirsh N, Ritter CL, Liu M, Nyati S, Pierce LJ, Jagsi R, Speers C. Mol Cancer Ther. 2019 Nov;18(11):2063-2073. doi: 10.1158/1535-7163.MCT-19-0520. Epub 2019 Aug 14. PMID: 31413177
Concurrent Veliparib With Chest Wall and Nodal Radiotherapy in Patients With Inflammatory or Locoregionally Recurrent Breast Cancer: The TBCRC 024 Phase I Multicenter Study. Jagsi R, Griffith KA, Bellon JR, Woodward WA, Horton JK, Ho A, Feng FY, Speers C, Overmoyer B, Sabel M, Schott AF, Pierce L; Translational Breast Cancer Research Consortium. J Clin Oncol. 2018 May 1;36(13):1317-1322. doi: 10.1200/JCO.2017.77.2665. Epub 2018 Mar 20. PMID: 29558281
Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer. Speers C, Zhao SG, Chandler B, Liu M, Wilder-Romans K, Olsen E, Nyati S, Ritter C, Alluri PG, Kothari V, Hayes DF, Lawrence TS, Spratt DE, Wahl DR, Pierce LJ, Feng FY. NPJ Breast Cancer. 2017 Aug 18;3:29. doi: 10.1038/s41523-017-0038-2. eCollection 2017. PMID: 28840192
Please contact Corey Speers, MD, PhD if you are interested in working with the Speers Lab.